STADA Arzneimittel AG
- Country
- 🇩🇪Germany
- Ownership
- Subsidiary
- Established
- 1895-01-01
- Employees
- 11.6K
- Market Cap
- -
- Website
- http://www.stada.com
Clinical Trials
2
Trial Phases
1 Phases
Drug Approvals
34
Drug Approvals
- Prev
- 1
- 2
- Next
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
News
Alvotech Appoints Linda Jónsdóttir as Chief Financial Officer
Alvotech, a global biosimilar medicines company, has appointed Linda Jónsdóttir as Chief Financial Officer, bringing 15 years of senior leadership experience from Marel food processing technology company.
Alvotech Acquires Swiss Packaging Specialist Ivers-Lee to Expand Biosimilar Manufacturing Capacity
Alvotech has acquired Ivers-Lee Group, a Swiss family-owned pharmaceutical packaging company founded in 1947, to expand its assembly and packaging capabilities ahead of three new biosimilar launches in 2025.
Alvotech Expands European Presence with Successful Nasdaq Stockholm Listing
Alvotech's Swedish Depository Receipts (SDRs) offering was multiple times oversubscribed, attracting over 3,000 new shareholders and raising approximately SEK 39 million.
EMA Accepts Bio-Thera's Marketing Application for BAT2506, First Chinese-Developed Golimumab Biosimilar
Bio-Thera Solutions achieves milestone as the European Medicines Agency accepts marketing application for BAT2506, marking the first golimumab biosimilar from a Chinese company submitted for EU approval.
EMA Accepts Alvotech's Biosimilar AVT03 for Prolia and Xgeva
The European Medicines Agency (EMA) has accepted Alvotech's Marketing Authorization Application for AVT03, a biosimilar candidate to Prolia and Xgeva.